| Ad5-N |
Beijing Institute of Basic Medical Sciences (China) |
Viral vector (adenovirus) |
Preclinical results |
| Ad5.SARS-CoV-2-S1 |
University of Pittsburgh (USA) |
Viral vector (adenovirus) |
Preclinical results
Preclinical results (vaccine adapted for variant, booster) |
| Ad5-S-nb2 |
Guangzhou Institutes of Biomedicine & Health & Guangzhou nBiomed (China) |
Viral vector (adenovirus) |
Preclinical results |
| AdC7-RBD-tr2 |
Chengdu Kanghua Biological Products (China) |
Viral vector (adenovirus) |
Preclinical results
Preclinical results |
| AdCoV2-S |
National Health Research Institutes (Taiwan) |
Viral vector (adenovirus) |
Preclinical results |
| BBV154 |
Bharat Biotech (India) |
Viral vector (adenovirus) |
Phase 1
Phase 2
Phase 2/3
Phase 3
Phase 3
(See ChAd-SARS-CoV-2-S below for preclinical) |
| BCPIV/S-2PM |
BioComo (Japan) |
Viral vector (parainfluenza) |
Preclinical results |
| BReC-CoV-2 |
West Virginia University (USA) |
Toxoid vector (diphtheria) |
Preclinical results |
| ChAdOx1 nCOV-19 |
Oxford University/AstraZeneca (UK) & Serum Institute of India (Covishield) |
Viral vector (adenovirus) |
Preclinical results (ferrets)
Preclinical results (hamsters, macaques)
Preclinical results (hamsters)
Phase 1
Phase 1 |
| ChAd-SARS-CoV-2-S |
Precision Virologics with Washington University in St Louis & NIAID (USA) |
Viral vector (adenovirus) |
Preclinical results (macaques)
Preclinical results (hamsters)
Preclinical results (mice)
(See BBV154 above for clinical trials of Bharat version) |
| ChAdTS-S |
National Institutes Food & Drug Control Beijing & West China Hospital (China) |
Viral vector (adenovirus) |
Preclinical results |
| CNUHV03-CA22 |
Chungnam National University (South Korea) |
Live attenuated |
Preclinical results |
| COH04S1 |
City of Hope & NCI (USA) |
Viral vector (Modified Vaccinia Ankara) |
Preclinical results
(See records for intramuscular version of this vaccine) |
| CuMVTT-RBD |
Saiba Biotech (Switzerland) |
Virus-like particles |
Preclinical results |
| CVXGA1 |
CyanVac and University of Georgia (USA) |
Viral vector (parainfluenza) |
Phase 1
Preclinical results
Preclinical results |
| DelNS1-RBD4N-DAF |
University of Hong Kong (China) |
Viral vector (influenza) |
Preclinical results |
| GAM-COVID-VAC (Sputnik V) |
Gamaleya Research Institute (Russia) |
Viral vectors x 2 (adenovirus) |
Phase 1/2
Phase 3 (or phase 2/3 – not clear) |
| GLS-5310 |
GeneOne Life Science (South Korea) |
DNA |
Phase 1 (Trials of other versions of this vaccine) |
| ΔNA(RBD)-Flu |
Fred Hutchinson Cancer Research Center & University of Washington (USA) |
Viral vector (influenza) |
Preclinical results |
| hA5-Covid-19 |
ImmunityBio (USA) |
Viral vector (adenovirus) |
Preclinical results
(See records for intramuscular version of this vaccine) |
| KaraVac |
Amirabad Virology Laboratory & Pasteur Institute Tehran (Iran) |
Live attenuated |
Preclinical results |
| LP18:RBD |
Chinese Academy of Agricultural Sciences Changchun (China) |
Bacterium vector (Lactobacillus plantarum) |
Preclinical results |
| MigVax-101 |
MigVax (Israel) |
Virus-like particles |
Preclinical results |
| MVA-SARS-2S |
Institute of Immunology Hannover (Germany) |
Viral vector (Modified Vaccinia Ankara) |
Preclinical results |
| MVC-COV1901 |
Medigen (Taiwan) |
Protein subunit |
Preclinical results
(See also results for the nanoemulsion adjuvant.) |
| NanoSTING-NS |
University of Houston & Auravax (USA) |
Protein subunit |
Preclinical results
Preclinical results |
| NDV-FLS |
University of Guelph (Canada) |
Viral vector (Newcastle Disease Virus) |
Preclinical results |
| NDV-HXP-S |
Icahn School of Medicine Mt Sinai (USA) |
Viral vector (Newcastle Disease Virus) |
Phase 1
Preclinical results
(See records for intramuscular form of this vaccine – see also Butanvac & Patria in this post, as well as versions in Thailand and Vietnam) |
| NDV-HXP-S – Butanvac |
Butantan Institute (Brazil) |
Viral vector (Newcastle Disease Virus) |
Preclinical results (See note above for the other versions of NDV-HXP-S) |
| NYVAC-KC-pfsSpike |
Arizona State University & University of Iowa (USA) |
Viral vector (NYVAC-KC) |
Preclinical results |
| ODN2006 |
National Institute of Infectious Diseases & Tokyo University of Science (Japan) |
Protein subunit |
Preclinical results |
| pQAC-CoV |
University of Wisconsin-Madison & Pan Genome Systems (USA) |
DNA |
Preclinical results |
| rMuV-preS-6P |
The Ohio State University (USA) |
Viral vector (mumps) |
Preclinical results |
| rNDV-S |
Lancaster University & Texas Biomedical Research Institute (USA) |
Viral vector (Newcastle Disease Virus) |
Preclinical results (See also results for other form) |
| rVSVSARS-CoV-2 |
Chinese Academy of Sciences & Shenzhen Kangtai Biotechnology (China) |
Viral vector (VSV) |
Preclinical results |
| SC-Ad6-1 |
Mayo Clinic & Tetherex Pharmaceuticals (USA) |
Viral vector (adenovirus) |
Phase 1
Preclinical results |
| scPR8-RBD-M2 |
BIOTEC, NSTDA & Chulalongkorn University (Thailand) |
Viral vector (influenza) |
Preclinical results |
| T4-CoV-2 |
The Catholic University of America & University of Texas (USA) |
Bacteriophage |
Preclinical results |
| (Unnamed) |
Abera Bioscience (Sweden), Vrije Universiteit Amsterdam (Netherlands) & Johns Hopkins University (USA) |
Extracellular vesicles |
Preclinical results
Errata notice |
| (Unnamed) |
Academy of Military Sciences & Chinese Academy of Sciences (China) |
Live attenuated |
Preclinical results |
| (Unnamed) |
ACM Biolabs (Singapore) |
Protein subunit |
Phase 1
Preclinical results |
| (Unnamed) |
BioTechMed-Graz & University of Graz (Austria) |
Extracellular vesicles (OMV) |
Preclinical results |
| (Unnamed) |
FARVET, Cayetano Heredia University (Peru) |
Viral vector (Newcastle Disease Virus) |
Preclinical results |
| (Unnamed) |
Chungbuk National University (South Korea) |
Protein subunit |
Preclinical results |
| (Unnamed) |
Georgia Institute of Technology & Emory University (USA) |
Protein subunit |
Preclinical results |
| (Unnamed) |
ID Pharma & National Institute of Infectious Diseases (Japan) |
Viral vector (F-deleted Sendai virus) |
Preclinical results |
| (Unnamed) |
INSERM (France) & CONICET (Argentina) |
Virus-like particles |
Preclinical results |
| (Unnamed) |
Institute of Experimental Medicine St Petersburg (Russia) |
Viral vector (influenza) |
Preclinical results |
| (Unnamed) |
Intravacc (Netherlands) |
Extracellular vesicles (OMV) |
Preclinical results |
| (Unnamed) |
Jeonbuk National University (South Korea) |
Replicon mRNA |
Preclinical results (mice)
Preclinical results (mice)
Preclinical results (hamsters) |
| (Unnamed) |
Mahidol University & Institute of Biological Products (Thailand) |
Protein subunit |
Preclinical results
Preclinical results |
| (Unnamed) |
McMaster University (Canada) |
Viral vector (adenovirus) |
Preclinical results |
| (Unnamed) |
National Cancer Institute NIH (USA) |
Protein subunit |
Preclinical results
Preclinical results (booster adapted for variant) |
| (Unnamed) |
National Engineering Research Center of Immunological Products (China) |
DNA |
Preclinical results |
| (Unnamed) |
National Institute of Allergy & Infectious Diseases (NIAID) NIH (USA) |
Viral vector (parainfluenza) |
Preclinical results
Preclinical results (pediatric primates) |
| (Unnamed) |
National Institute of Allergy & Infectious Diseases (NIAID) NIH (USA) |
Viral vector (Modified Vaccinia Ankara) |
Preclinical results |
| (Unnamed) |
Ohio State University (USA) |
Protein subunit |
Preclinical results |
| (Unnamed) |
Oragenics & National Research Council (Canada) |
Protein subunit |
Preclinical results |
| (Unnamed) |
Rutgers Cancer Institute of New Jersey (USA) |
Bacteriophage |
Preclinical results |
| (Unnamed) |
Shanghai Bovax Biotech & GeneSail Biotech (China) |
Viral vector (adenovirus) |
Preclinical results |
| (Unnamed) |
Sichuan University (China) |
Protein subunit |
Preclinical results
Preclinical results |
| (Unnamed) |
Stanford University (USA) |
DNA |
Preclinical results |
| (Unnamed) |
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen (China) |
Viral vector (influenza) |
Preclinical results |
| (Unnamed) |
Sun Yat-Sen University & Chinese Academy of Sciences (China) |
Protein subunit |
Preclinical results |
| (Unnamed) |
Texas Biomedical Research Institute (USA) |
Live attenuated |
Preclinical results |
| (Unnamed) |
TheraVectys & Pasteur Institute (France) |
Viral vector (Lentivirus) |
Preclinical results (mice)
Preclinical results (mice)
Preclinical results (mice, hamsters) |
| (Unnamed) |
University of California Los Angeles (UCLA) (USA) |
Bacterium vector (ΔcapB) |
Preclinical results |
| (Unnamed) |
University of Hong Kong (Hong Kong) |
Protein subunit |
Preclinical results |
| (Unnamed) |
University of Hong Kong (Hong Kong) |
Live attenuated |
Preclinical results |
| (Unnamed) |
University of Manitoba (Canada) |
Viral vector (recombinant VSV) |
Preclinical results |
| (Unnamed) |
North Carolina State University, University of North Carolina, & Duke University (USA) |
Extracellular vesicles |
Preclinical results |
| (Unnamed) |
University of North Carolina-Chapel Hill & North Carolina State University (USA) |
Protein subunit |
Preclinical results |
| (Unnamed) |
University of Texas (USA) |
Viral vector (parainfluenza) |
Preclinical results |
| (Unnamed) |
University of Virginia & Mayo Clinic |
Viral vector (adenovirus) |
Preclinical results |
| (Unnamed) |
University of Wisconsin-Madison (USA) |
Protein subunit |
Preclinical results |
| (Unnamed) |
Vyriad & Imanis Life Sciences (USA) |
Viral vector (VSV) |
Preclinical results |
| (Unnamed X 2) |
Yale University & Xanadu Bio (USA) |
Protein subunit & PACE encapsulating mRNA |
Preclinical results |
| (Unnamed) |
Yunnan Key Laboratory & IMBCAMS (China) |
Peptide |
Preclinical results |
| VSV-SARS2-EBOV |
National Institute of Allergy and Infectious Diseases (NIAID) NIH & University of California Irvine (USA) |
Viral vector (VSV) |
Preclinical results (hamsters)
Preclinical results (macaques) |
